MARKET

AEZS

AEZS

Aeterna Zentaris Inc
NASDAQ
3.790
+0.050
+1.34%
Opening 11:27 02/07 EST
OPEN
3.760
PREV CLOSE
3.740
HIGH
3.790
LOW
3.760
VOLUME
1.18K
TURNOVER
3.35K
52 WEEK HIGH
10.99
52 WEEK LOW
2.890
MARKET CAP
18.40M
P/E (TTM)
-1.7690
1D
5D
1M
3M
1Y
5Y
Analysts Offer Insights on Healthcare Companies: Aeterna Zentaris (AEZS), Arrowhead Pharmaceuticals (ARWR) and Enlivex (ENLV)
TipRanks · 01/23 11:20
Aeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19
Benzinga · 01/17 17:53
BRIEF-Aeterna Zentaris Provides Business Update
Reuters · 01/17 13:53
Aeterna Zentaris (AEZS) Reports Q3 Loss, Tops Revenue Estimates
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -2.94% and 38.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03/2022 14:15
Aeterna Zentaris GAAP EPS of -$0.70 misses by $0.02, revenue of $1.9M beats by $0.57M
Seekingalpha · 11/03/2022 13:02
AEterna Zentaris Q3 EPS $(0.70) Down From $(0.25) YoY
Benzinga · 11/03/2022 12:25
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS) (“Aet...
GlobeNewswire · 11/03/2022 12:05
Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk
Aeterna Zentaris (NASDAQ:AEZS) on Monday said it would rega...
Seekingalpha · 08/29/2022 14:12
More
About AEZS
Aeterna Zentaris Inc. is a specialty biopharmaceutical company, which is engaged in commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The Company focuses on the commercialization of macimorelin in Asia and the rest of the world.

Webull offers kinds of AEterna Zentaris Inc. (USA) stock information, including NASDAQ:AEZS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEZS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AEZS stock methods without spending real money on the virtual paper trading platform.